Aptose former director exits options in Hammi deal
Aptose Biosciences Inc. former director Vincent Mark D. reported multiple dispositions to the issuer of stock options and a small number of common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Aptose Biosciences Inc. former director Vincent Mark D. reported multiple dispositions to the issuer of stock options and a small number of common shares. These transactions reflect cancellation of option awards and 14 common shares in connection with a business arrangement where a Hammi Pharmaceuticals Co. Ltd. subsidiary acquired all outstanding Aptose shares at C$2.41 per share. Following these dispositions, the filing shows no remaining direct holdings or derivative positions for this former director.
Insider Trade Summary
Disposition: 522,347 shares
Disposition
11 txns
Insider
Vincent Mark D.
Role
Insider
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Director Stock Option (Right to Buy) | 3,333 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 100,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 50,000 | $0.00 | $0.00 |
| Disposition | Director Option Grant | 154,000 | $0.00 | $0.00 |
| Disposition | Stock Options (Right to Buy) | 40,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 10,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 5,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 60,000 | $0.00 | $0.00 |
| Disposition | Director Stock Option (Right to Buy) | 50,000 | $0.00 | $0.00 |
| Disposition | Common Shares | 14 | $1.72 | $24.08 |
Holdings After Transaction:
Director Stock Option (Right to Buy) — 0 contracts (Direct);
Director Option Grant — 0 contracts (Direct);
Stock Options (Right to Buy) — 0 contracts (Direct);
Common Shares — 0 shares (Direct)
Footnotes (3)
- F1. Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation ("Hammi") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share.
- F2. Converted from Canadian price of C$2.41 per share using exchange rate of C$1.4 = US$1.00.
- F3. Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually beginning on the second anniversary of the grant date.
Key Figures
Disposition events: 11 transactions
Common shares disposed: 14 shares at US$1.72
Acquisition price: C$2.41 per share
+5 more
8 metrics
Disposition events
11 transactions
All coded as disposition to issuer on 2026-06-30 and 2026-06-13
Common shares disposed
14 shares at US$1.72
Common Shares transaction on 2026-06-13
Acquisition price
C$2.41 per share
Hammi subsidiary acquisition of all outstanding Aptose shares
Exchange rate
C$1.4 = US$1.00
Used to convert C$2.41 per share into U.S. dollars
Option block
50,000 options at US$4.38
Director Stock Option (Right to Buy), expiration 2031-01-04, disposed
Largest option grant
154,000 options at US$6.91
Director Option Grant, expiration 2030-01-30, disposed
Recent option grant
3,333 options at US$1.97
Director Stock Option (Right to Buy), expiration 2034-02-05, disposed
Post-transaction holdings
0 shares, 0 derivatives
Total shares following each transaction reported as 0.0000
Key Terms
Disposition to issuer, Director Stock Option (Right to Buy, business arrangement agreement, Hammi Pharmaceuticals Co. Ltd, +2 more
6 terms
Disposition to issuer financial
"transaction_code_description: "Disposition to issuer" for each transaction"
Director Stock Option (Right to Buy financial
"security_title: "Director Stock Option (Right to Buy)" on multiple lines"
business arrangement agreement regulatory
"Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement"
Hammi Pharmaceuticals Co. Ltd financial
"business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd, a South Korean corporation"
exchange rate financial
"Converted from Canadian price of C$2.41 per share using exchange rate of C$1.4 = US$1.00"
Exchange rate is the price of one currency expressed in another—for example, how many euros you receive for one US dollar. It matters to investors because changes in that price alter the reported profits, costs and value of assets for companies and portfolios that operate or hold money across borders; think of it like switching measurement units, where the same item can look bigger or smaller depending on the unit used.
Options vest financial
"Options vest 50% on the first anniversary of grant date; remaining options vest 1/3 annually"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Aptose Biosciences (APTOF) report in this Form 4?
The Form 4 shows former director Vincent Mark D. disposed of multiple stock option grants and 14 common shares. All transactions are coded as “Disposition to issuer,” reflecting positions being given up rather than open‑market sales.
What happened to the Aptose Biosciences (APTOF) stock options held by the former director?
The Form 4 lists several Director Stock Option and Director Option Grant awards as disposed of to the issuer. These covered various strike prices and expiration dates, and after these transactions, the filing shows zero options remaining for the reporting person.
Does the Aptose Biosciences (APTOF) Form 4 show any remaining holdings for the former director?
No remaining holdings are shown. Each reported derivative and non‑derivative transaction lists total shares following the transaction as 0.0000, indicating the former director no longer holds Aptose common shares or related options.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates